Autopsy report · NCT04547985

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

“We are terminating the study due to low accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 2 years 9 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Weill Medical College of Cornell University

Sponsor type

University, hospital or other

Conditions

Prolonged Grief Disorder

Interventions

Naltrexone HCl 50 MG Oral Tablet; Placebo

Participants

9

Sites

1

Countries

United States

Trials that died the same way

• Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
  “The study was terminated due to low accrual.” (86% match in meaning)
• Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
  “Study stopped due to low accrual.” (85% match in meaning)
• Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
  “Study terminated due to low accrual.” (84% match in meaning)
• Pembrolizumab + Idelalisib for Lung Cancer Study
  “The study was terminated due to poor accrual.” (82% match in meaning)
• Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy
  “Because of many unseen obstacles resulted in poor accrual, study is terminated.” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.